GLP-1 (Semaglutide)
Reported Onset
1–4 weeks (appetite suppression), 4–12 weeks (weight loss)
Primary Use
Significant weight loss via appetite suppression and metabolic improvement.
Dose
0.25mg - 2.4mg
Frequency
Weekly
Cagrilintide
Reported Onset
2–4 weeks
Primary Use
Appetite control and weight management, especially synergistic with GLP-1 agonists.
Dose
0.3mg - 2.4mg
Frequency
Weekly
Community Verdict
CagriSema combination components — comparing the two individually. The community generally selects between GLP-1 (Semaglutide) and Cagrilintide based on their specific goals and experience. Both compounds are available through physician-supervised protocols at Alukard, where a physician can help determine which is most appropriate for your situation.
Get a Physician-Supervised Protocol for GLP-1 (Semaglutide) or Cagrilintide at Alukard
Community experiences are a starting point — but a physician-supervised protocol from Alukard gives you pharmaceutical-grade compounds, proper dosing, lab monitoring, and the safety of medical oversight.
MD
Supervised
GMP
Certified
Labs
Monitoring
COA
Verified